Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

This is a prospective, open, single-center, single-arm phase II clinical study with common EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory.To evaluate the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and/or micropapillary component ≥10%, and/or airway spread).

Trial Details

NCT ID
NCT05686434
Phase
PHASE2
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Osimertinib
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • The subject will voluntarily sign the informed consent in person, and provide the informed consent before any specific study procedures;
  • Male and female, ≥18 years old;
  • Primary non-squamous NSCLC confirmed histologically by the central laboratory;
  • Brain imaging examinations should be performed before surgery or enrollment;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →